Clinical Trial Comparing Catheter Lock Solutions TaurolockTMHep 100 and Heparin 100 IE/ml.

PHASE4UnknownINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 31, 2016

Study Completion Date

December 31, 2016

Conditions
Catheter-related Bloodstream Infection (CRBSI) Nos
Interventions
DEVICE

TaurolockTMHep100

2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.

DEVICE

Heparin 100 IE/ml

2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.

Trial Locations (1)

2100

Rigshospitalet, abdominalcentret, Medicinsk Gastroenterologisk klinik CA, 2121, Copenhagen

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

TauroPharm

INDUSTRY

lead

Palle Bekker Jeppesen

OTHER